Identification of TP53 germline variants in pediatric patients undergoing tumor testing: strategy and prevalence

Author:

Luo Minjie12ORCID,Wong Derek1,Zelley Kristin3,Wu Jinhua1,Schubert Jeffery1,Denenberg Elizabeth H1,Fanning Elizabeth A1,Chen Jiani1,Gallo Daniel1,Golenberg Netta1,Patel Maha1,Conlin Laura K12,Maxwell Kara N45ORCID,Wertheim Gerald B12,Surrey Lea F12,Zhong Yiming12,Brodeur Garrett M36,MacFarland Suzanne P36,Li Marilyn M1236

Affiliation:

1. Division of Genomic Diagnostics, Children’s Hospital of Philadelphia , Philadelphia, PA, USA

2. Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA, USA

3. Division of Oncology, Department of Pediatrics, Children’s Hospital of Philadelphia , Philadelphia, PA, USA

4. Department of Medicine, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA, USA

5. Corporal Michael J. Crescenz Veterans Affairs Medical Center , Philadelphia, PA, USA

6. Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA, USA

Abstract

Abstract Background TP53 alterations are common in certain pediatric cancers, making identification of putative germline variants through tumor genomic profiling crucial for disease management. Methods We analyzed TP53 alterations in 3123 tumors from 2788 pediatric patients sequenced using tumor-only or tumor-normal paired panels. Germline confirmatory testing was performed when indicated. Somatic and germline variants were classified based on published guidelines. Results In 248 tumors from 222 patients, 284 tier 1/2 TP53 sequence and small copy number variants were detected. Following germline classification, 86.6% of 142 unique variants were pathogenic or likely pathogenic. Confirmatory testing on 118 patients revealed germline TP53 variants in 28 of them (23 pathogenic or likely pathogenic and 5 of uncertain significance), suggesting a minimum Li-Fraumeni syndrome incidence of 0.8% (23/2788) in this cohort, 10.4% (23/222) in patients with TP53 variant–carrying tumors, and 19.5% (23/118) with available normal samples. About 25% (7/28) of patients with germline TP53 variants did not meet Li-Fraumeni syndrome diagnostic or testing criteria, while 20.9% (28/134) with confirmed or inferred somatic origins did. TP53 biallelic inactivation occurred in 75% of germline carrier tumors and was also prevalent in other groups, causing an elevated tumor-observed variant allelic fraction. Somatic evidence, however, including low variant allele fraction correctly identified only 27.8% (25/90) of patients with confirmed somatic TP53 variants. Conclusion The high incidence and variable phenotype of Li-Fraumeni syndrome in this cohort highlights the importance of assessing germline status of TP53 variants identified in all pediatric tumors. Without clear somatic evidence, distinguishing somatic from germline origins is challenging. Classifying germline and somatic variants should follow appropriate guidelines.

Publisher

Oxford University Press (OUP)

Reference36 articles.

1. Clinical utility of custom-designed NGS panel testing in pediatric tumors;Surrey;Genome Med,2019

2. Pediatric somatic tumor sequencing identifies underlying cancer predisposition;MacFarland;J Clin Oncol Precis Oncol,2019

3. Germline mutations in predisposition genes in pediatric cancer;Zhang;N Engl J Med,2015

4. The landscape of genomic alterations across childhood cancers;Gröbner;Nature,2018

5. Pediatric cancer predisposition and surveillance: an overview, and a tribute to Alfred G. Knudson Jr;Brodeur;Clin Cancer Res,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3